MedPath

Triamcinolone

Generic Name
Triamcinolone
Brand Names
Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Kourzeq, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta
Drug Type
Small Molecule
Chemical Formula
C21H27FO6
CAS Number
124-94-7
Unique Ingredient Identifier
1ZK20VI6TY
Background

Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.

Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.

Indication

肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱,故一般不用作肾上腺皮质功能减退的替代治疗。

Associated Conditions
Acne, Acne Vulgaris, Acute Gouty Arthritis, Allergic Contact Dermatitis, Allergic Rhinitis (AR), Allergic Skin Reaction, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aphthous Stomatitis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Bullous dermatitis herpetiformis, Chronic Eczema, Chronic Inflammatory Skin Diseases, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dental Cavity, Dermatitis, Dermatomyositis (DM), Diaper Rash, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Erythroderma, Fungal Infections, Fungal infectious disorders of the Beard, Fungal skin infection, Gingivitis, Haemorrhoids, Hemangiomas, Hypercalcemia, Inflammation of Mouth, Intertrigo, Itching of the Anus, Itching of the External Genitalia, Itching of the Foot, Itching of the genitals, Itching of the hand, Juvenile Idiopathic Arthritis (JIA), Keloids Scars, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lymphoma, Macular Edema, Mycosis Fungoides (MF), Mycotic Eczema, Necrobiosis lipoidica diabeticorum, Neurodermatitis, Nummular Dermatitis, Ocular Inflammation, Ophthalmia, Sympathetic, Oral Erosive Lichen Planus, Otitis Externa, Pemphigus, Pericarditis, Polymyositis, Postherpetic Neuralgia, Primary adrenocortical insufficiency, Proteinuria, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Purulent Wounds, Pyoderma caused by susceptible bacteria, Regional Enteritis, Rheumatoid Arthritis, Ringworm Folliculitis, Seborrheic Dermatitis, Seborrheic Dermatitis, Eczematous, Secondary Impetiginization, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Skin chapped, Stomatitis, Denture, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Tinea Corporis, Transfusion Reactions, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Urticaria, Uveitis, Wound Infections, Acute Bursitis, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Corticosteroid-responsive dermatoses, Cutaneous candidiasis, Cystic tumour of the ganglia, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Oral infections, Oral lesions, Severe Erythema multiforme, Subacute Dermatitis, Eczematous, Symptomatic Sarcoidosis, Ulceration of the mouth, Ulcerative stomatitis

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

Phase 2
Completed
Conditions
Diabetic Retinopathy
First Posted Date
2005-10-03
Last Posted Date
2008-03-04
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
10
Registration Number
NCT00231023
Locations
🇺🇸

National Eye Institute (NEI), Bethesda, Maryland, United States

Triamcinolone vs. Laser for Diabetic Macular Edema

Not Applicable
Completed
Conditions
DIABETIC MACULAR EDEMA
Interventions
First Posted Date
2005-09-30
Last Posted Date
2023-12-28
Lead Sponsor
University of Oklahoma
Target Recruit Count
11
Registration Number
NCT00229931
Locations
🇺🇸

Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States

PST/Laser v. Laser Alone for CSME

Phase 2
Conditions
Diabetic Retinopathy
First Posted Date
2005-09-30
Last Posted Date
2005-09-30
Lead Sponsor
Edward Hines Jr. VA Hospital
Target Recruit Count
60
Registration Number
NCT00229918
Locations
🇺🇸

Edward Hines Jr. VAH, Hines, Illinois, United States

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Phase 1
Completed
Conditions
Maculopathy, Age-Related
First Posted Date
2005-09-21
Last Posted Date
2012-10-24
Lead Sponsor
Manhattan Eye, Ear & Throat Hospital
Registration Number
NCT00211419
Locations
🇺🇸

Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

Phase 2
Completed
Conditions
Diabetic Macular Oedema
First Posted Date
2005-09-14
Last Posted Date
2005-09-14
Lead Sponsor
University of Sydney
Target Recruit Count
70
Registration Number
NCT00167518
Locations
🇦🇺

Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney, New South Wales, Australia

Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

Phase 2
Conditions
Age-Related Macular Degeneration
First Posted Date
2005-09-08
Last Posted Date
2007-07-30
Lead Sponsor
Canadian Retinal Trials Group
Target Recruit Count
120
Registration Number
NCT00148551
Locations
🇨🇦

Eye Care Centre, Vancouver, British Columbia, Canada

A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema

Phase 2
Completed
Conditions
Diabetic Macular Oedema
First Posted Date
2005-09-07
Last Posted Date
2010-06-23
Lead Sponsor
University of Sydney
Target Recruit Count
54
Registration Number
NCT00148265
Locations
🇦🇺

Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney, New South Wales, Australia

Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

Phase 2
Completed
Conditions
Diabetic Macular Oedema
First Posted Date
2005-09-07
Last Posted Date
2010-06-30
Lead Sponsor
University of Sydney
Target Recruit Count
64
Registration Number
NCT00148330
Locations
🇦🇺

Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney, New South Wales, Australia

An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial
First Posted Date
2005-08-22
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Target Recruit Count
460
Registration Number
NCT00132925
Locations
🇺🇸

Sanofi-Aventis, Inc., Bridgewater, New Jersey, United States

Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage

Phase 3
Completed
Conditions
Retinal Vein Occlusion
Macular Edema, Cystoid
Macular Edema
First Posted Date
2005-03-21
Last Posted Date
2008-03-04
Lead Sponsor
National Eye Institute (NEI)
Target Recruit Count
1260
Registration Number
NCT00106132
Locations
🇺🇸

National Eye Institute (NEI), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath